dragon

Azerbaijan Medical Journal

Aim and Scope

Azerbaijan Medical Journal

The Azerbaijan Medical Journal (AMJ) is a peer-reviewed, open-access monthly publication dedicated to advancing medical science and clinical practice through the dissemination of high-quality, original research. The Journal aims to serve as a global platform for researchers, clinicians, and healthcare professionals to share innovative findings, critical reviews, and evidence-based insights that contribute to the understanding, prevention, diagnosis, and treatment of diseases.

AMJ welcomes submissions across a broad spectrum of medical disciplines, including but not limited to:

The Journal particularly encourages contributions from early-career researchers, multidisciplinary teams, and authors from underrepresented regions. All manuscripts undergo rigorous double-blind peer review to ensure scientific integrity, methodological soundness, and relevance to contemporary medical challenges.We invite authors worldwide to submit original articles, review papers, case reports, brief communications, and study protocols that align with the Journal’s mission of promoting excellence, equity, and accessibility in medical scholarship.

📝 Official Submission Process

Manuscripts must be submitted officially through our online system. Please complete the REGISTRATION FORM on our website first to access your Author Dashboard. You may then submit your manuscript for an initial review by our dedicated editorial team to assess its compliance with our journal's policies and scope.

Step-by-Step Submission:
  1. 1. Complete registration form
  2. 2. Access Author Dashboard
  3. 3. Submit manuscript online
  4. 4. Initial editorial assessment
💡 Need Help?

For technical assistance with submission or registration, please contact:

For general editorial questions or policy inquiries:

Latest Articles

Azerbaijan Medical Journal

AMJ-21-12-2025-66666
Gut Microbiome Signatures Predicting Immune Checkpoint InhibitorResponse in Metastatic Melanoma. A Multi-Omics Machine Learning Analysis

Background: Response rates to immune checkpoint inhibitors (ICIs) in metastatic melanoma remain heterogeneous(40-60%), with gut microbiome composition emerging as a key modulator of anti-tumor immunity. However,predictive microbiome signatures lack validation across diverse cohorts and omic layers. Objectives: To develop and validate a multi-omics model integrating gut microbiome, metabolomic, and...

Read More Azerbaijan Medical Journal • 21-12-2025
dragon